Singapore Gains Momentum As Major R&D, Manufacturing Hub; Sees Double-digit Pharma Sector Growth
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Output of Singapore's biomedical manufacturing cluster increased 14.8 percent last year, according to Singapore's Economic Development Board. Within the cluster, the pharmaceuticals segment grew 15.6 percent with higher levels of production of active pharmaceutical ingredients. Output of the medical technology segment edged up 0.8 percent to meet export orders for surgical and medical instruments
You may also be interested in...
Deals of the Week: Ante Up For Antisense, Pharma Places Another Isis Bet
The biotech brings Roche on as its seventh biopharma partner, building on the more than $5 billion in potential partnership revenue the biotech had already amassed. If all goes as planned, Isis will add five marketed products within the next five years to the newly approved Kynamro. But Wall Street doesn’t expect Isis’ revenues to increase much anytime soon. Plus more notable deals this week…
GSK Says "Unique" Collaboration With Singapore Academics Aimed Squarely At Drug Discovery
SINGAPORE - GlaxoSmithKline said four new drug research collaborations between Singapore-based academics and GSK's global drug discovery network are "unique" alliances for the firm, pairing seasoned researchers from GSK's global network with promising academic work to bring new drugs to the market
GSK Says "Unique" Collaboration With Singapore Academics Aimed Squarely At Drug Discovery
SINGAPORE - GlaxoSmithKline said four new drug research collaborations between Singapore-based academics and GSK's global drug discovery network are "unique" alliances for the firm, pairing seasoned researchers from GSK's global network with promising academic work to bring new drugs to the market